Discover investment opportunities in Most Active Stocks Under $20 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Most Active Stocks Under $20 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Most Active Stocks Under $20 using our Smart AI Filter.
4 stocks found for "Most Active Stocks Under $20"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.17 Risk measure | ±100.0% Price volatility | -4.1 Valuation | 0.00% Annual yield | |||
0.79 Risk measure | ±66.3% Price volatility | -11.4 Valuation | 0.00% Annual yield | |||
0.79 Risk measure | ±46.9% Price volatility | -62.2 Valuation | 0.00% Annual yield | |||
0.42 Risk measure | ±21.7% Price volatility | 6.9 Valuation | 12.99% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreAmid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.
Read moreQ: What trends may influence the stock price of ARTL?
A: ARTL's price may be influenced by trends in the biotechnology sector, particularly developments in their drug pipeline and clinical trial results. Regulatory approvals and partnerships with larger pharmaceutical companies could also impact its valuation.
Q: How might ATAI's strategic partnerships affect investor interest?
A: ATAI's strategic partnerships in the mental health biotech space could enhance investor interest by potentially accelerating drug development, leveraging research capabilities, and opening doors to new markets, which may suggest future growth opportunities.
Q: What economic factors could impact HURA's performance?
A: HURA, an ETF focused on uranium, could be impacted by changes in nuclear energy policies, uranium prices, and global energy demand shifts, particularly if countries increase nuclear power to meet climate goals.
Q: Why are some investors interested in SERV’s financial health?
A: Investors may focus on SERV's financial health due to its position in the service industry, where maintaining cash flows and managing debt efficiently can indicate operational stability and resilience against economic downturns.
Q: What sector-specific risks could ZSPC face?
A: ZSPC, operating in the agricultural sector, could face risks from fluctuating commodity prices, regulatory changes, and climate-related impacts, which might affect production and profitability.
Q: How does XAIR's involvement in medical technology influence its volatility?
A: XAIR's engagement in innovative medical tech may cause higher volatility due to the impact of R&D successes or failures, regulatory approvals, and competitive pressure in the healthcare sector.